Drawing for SCANCELL

USPTO serial 50072440

SCANCELL

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with SCANCELL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Andrew D. Price

Andrew D. Price Venable LLPP.O. Box 34385Washington, DC 20043-4385United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, for the treatment of cancer; therapeutic preparations and substances, namely, for the treatment of cancer; chemical preparations, namely, for the treatment of cancer; diagnostic reagents for medical use; DNA, antibodies and proteins that stimulate high-avidity T-cells responses for therapeutic and medical use, namely, for the treatment of cancer; pharmaceutical compounds for treatment of cancer; vaccine preparations and substances; peptide vaccines; DNA vaccines and substances; Therapeutic preparations and substances for medical use, namely, DNA, antibodies and proteins for use in expressing epitopes, for use in encoding, for use in vectoring to target cells, and for use in stimulating cells; vaccines, including DNA vaccines; Therapeutic preparations for use in T-cell therapy and chimeric antigen receptor T-cell therapy to treat cancerACTIVE—
042Pharmaceutical testing and clinical trials for others; provision of information and consultancy in relation to the aforesaid services; scientific and technological services, namely, research and design in the field of drug development for the treatment of cancer; pharmaceutical research and development services; research and development in the biotechnology fieldACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 28, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 26, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 26, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance